Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sargramostim inhalation efficacy trial in autoimmune pulmonary alveolar proteinosis
jRCTs031220127Completed
- Sponsor
- Nobelpharma Co., Ltd.
- Start
- Aug 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of sargramostim in autoimmune pulmonary alveolar proteinosis (aPAP), sponsored by Nobelpharma Co., Ltd. Started Aug 2022; status: completed.
02
Drugs
sargramostim
03
Conditions
autoimmune pulmonary alveolar proteinosis (aPAP)
Beyond the preview
Go deeper on jRCTs031220127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031220127.